Gender differences in central serous chorioretinopathy based on the new multimodal imaging classification.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
04 Nov 2023
04 Nov 2023
Historique:
received:
22
01
2023
accepted:
24
10
2023
revised:
11
10
2023
medline:
5
11
2023
pubmed:
5
11
2023
entrez:
5
11
2023
Statut:
aheadofprint
Résumé
To analyse the gender-specific differences in central serous chorioretinopathy (CSCR) based on a new multimodal imaging classification system. This was a retrospective, multicentric, longitudinal, observational study in patients with a diagnosis of unilateral or bilateral CSCR. Visual acuity outcomes and differences based on 'Simple' and 'Complex' CSCR were analysed. The occurrence of choroidal neovascularization (CNVM) and number of recurrences were also compared. Regression analysis was used to evaluate baseline predictors of final visual acuity. The study included 109 eyes of 58 patients (55 eyes of 28 female patients and 54 eyes of 30 male patients). Simple CSCR was seen in 8 (14.8%) eyes and 21 (38.2%) eyes in male and female groups respectively, while complex CSCR was seen in 46 (85.2%) eyes and 34 (61.8%) eyes in male and female groups respectively (p = 0.005). Recurrence was more commonly seen in males (34 eyes) than in females (23 eyes) (p = 0.03). Males (96.7%) were also significantly more likely to have a bilateral presentation (78.6% in females) (p = 0.03). Conversely, CNVM was more commonly seen in female eyes (8 eyes) than male eyes (4 eyes) (p = 0.23). On multivariable regression analysis, factors affecting reduced need for treatment were history of steroid use, good visual acuity at baseline, and simple CSCR. Factors affecting good final visual acuity were history of steroid use, good visual acuity at baseline, and younger age. Males tended to have complex CSCR and recurrence compared to the female sub-group, while females exhibited CNVM more commonly than males.
Identifiants
pubmed: 37925559
doi: 10.1038/s41433-023-02812-5
pii: 10.1038/s41433-023-02812-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
Références
Von Graefe A. Ueber centrale recidivierende retinitis. Graefes Arch Clin Exp Ophthalmol. 1866;12:211–5.
Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol. 1984;68:815–20.
doi: 10.1136/bjo.68.11.815
pubmed: 6541945
pmcid: 1040477
Sartini F, Figus M, Nardi M, Casini G, Posarelli C. Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options. Eye. 2019;33:1035–43.
doi: 10.1038/s41433-019-0381-7
pubmed: 30824822
pmcid: 6707196
Hanumunthadu D, Tan AC, Singh SR, Sahu NK, Chhablani J. Management of chronic central serous chorioretinopathy. Indian J Ophthalmol. 2018;66:1704.
doi: 10.4103/ijo.IJO_1077_18
pubmed: 30451170
pmcid: 6256894
Sahoo NK, Lupidi M, Goud A, Gangakhedkar S, Cardillo Piccolino F, Chhablani J. One-year outcome of cystoid macular degeneration in central serous chorioretinopathy. Eur J Ophthalmol. 2022;32:2347–54.
doi: 10.1177/11206721211046497
Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S, Group CSCCCS. Risk factors for central serous chorioretinopathy: a case–control study. Ophthalmology. 2004;111:244–9.
doi: 10.1016/j.ophtha.2003.09.024
pubmed: 15019370
Chatziralli I, Kabanarou SA, Parikakis E, Chatzirallis A, Xirou T, Mitropoulos P. Risk factors for central serous chorioretinopathy: multivariate approach in a case-control study. Curr Eye Res. 2017;42:1069–73.
doi: 10.1080/02713683.2016.1276196
pubmed: 28306346
Matet A, Daruich A, Zola M, Behar-Cohen F. Risk factors for recurrences of central serous chorioretinopathy. Retina. 2018;38:1403–14.
doi: 10.1097/IAE.0000000000001729
pubmed: 28570485
Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58:103–26.
doi: 10.1016/j.survophthal.2012.07.004
pubmed: 23410821
pmcid: 3574296
Yoneyama S, Fukui A, Sakurada Y, Terao N, Shijo T, Kusada N, et al. Distinct characteristics of central serous chorioretinopathy according to gender. Sci Rep. 2022;12:1–8.
doi: 10.1038/s41598-022-14777-8
Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008;115:169–73.
doi: 10.1016/j.ophtha.2007.02.032
pubmed: 18166410
Ersoz MG, Arf S, Hocaoglu M, Muslubas IS, Karacorlu M. Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients. Br J Ophthalmol. 2019;103:725–9.
doi: 10.1136/bjophthalmol-2018-312431
pubmed: 30002072
Todd KC, Hainsworth DP, Lee LR, Madsen RW. Longitudinal analysis of central serous chorioretinopathy and sex. Can J Ophthalmol. 2002;37:405–8.
doi: 10.1016/S0008-4182(02)80043-6
pubmed: 12516721
Hanumunthadu D, Van Dijk EH, Gangakhedkar S, Goud A, Cheung CMG, Cherfan D, et al. Gender variation in central serous chorioretinopathy. Eye. 2018;32:1703–9.
doi: 10.1038/s41433-018-0163-7
pubmed: 29988073
pmcid: 6224519
van Dijk EH, Schellevis RL, van Bergen MG, Breukink MB, Altay L, Scholz P, et al. Association of a haplotype in the NR3C2 gene, encoding the mineralocorticoid receptor, with chronic central serous chorioretinopathy. JAMA Ophthalmol. 2017;135:446–51.
doi: 10.1001/jamaophthalmol.2017.0245
pubmed: 28334414
pmcid: 5847108
Baker ME, Katsu Y. Progesterone: an enigmatic ligand for the mineralocorticoid receptor. Biochem Pharm. 2020;177:113976.
doi: 10.1016/j.bcp.2020.113976
pubmed: 32305433
Spaide RF, Cheung CMG, Matsumoto H, Kishi S, Boon CJ, van Dijk EH, et al. Venous overload choroidopathy: a hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retin Eye Res. 2021;86:100973.
doi: 10.1016/j.preteyeres.2021.100973
pubmed: 34029721
Bacci T, Oh DJ, Singer M, Sadda S, Freund KB. Ultra-widefield indocyanine green angiography reveals patterns of choroidal venous insufficiency influencing pachychoroid disease. Invest Ophthalmol Vis Sci. 2022;63:17.
doi: 10.1167/iovs.63.1.17
pubmed: 35019945
pmcid: 8762674
Imanaga N, Terao N, Nakamine S, Tamashiro T, Wakugawa S, Sawaguchi K, et al. Scleral thickness in central serous chorioretinopathy. Ophthalmol Retin. 2021;5:285–91.
doi: 10.1016/j.oret.2020.07.011
Buckhurst HD, Gilmartin B, Cubbidge RP, Logan NS. Measurement of scleral thickness in humans using anterior segment optical coherent tomography. PloS One. 2015;10:e0132902.
doi: 10.1371/journal.pone.0132902
pubmed: 26218188
pmcid: 4517791
Bousquet E, Torres-Villaros H, Provost J, Elalouf M, Gigon A, Mantel I, et al. Clinical characteristics and multimodal imaging findings of central serous chorioretinopathy in women versus men. J Clin Med. 2022;11:1706.
doi: 10.3390/jcm11061706
pubmed: 35330031
pmcid: 8954406
Chhablani J, Cohen FB, Aymard P, Beydoun T, Bousquet E, Daruich-Matet A, et al. Multimodal imaging-based central serous chorioretinopathy classification. Ophthalmol Retin. 2020;4:1043–6.
doi: 10.1016/j.oret.2020.07.026
Sahoo NK, Parameshwarappa DC, Jhingan M, Tatti F, Iovino C, Peiretti E. Interobserver agreement of novel classification of central serous chorioretinopathy. Cureus. 2022;14:e25925.
pubmed: 35844339
pmcid: 9281466
Chhablani J, Behar-Cohen F. Validation of central serous chorioretinopathy multimodal imaging-based classification system. Graefes Arch Clin Exp Ophthalmol. 2022;260:1161–9.
doi: 10.1007/s00417-021-05452-1
pubmed: 34669028
Singh SR, Matet A, Van Dijk EH, Daruich A, Fauser S, Yzer S, et al. Discrepancy in current central serous chorioretinopathy classification. Br J Ophthalmol. 2019;103:737–42.
doi: 10.1136/bjophthalmol-2018-312435
pubmed: 30002069
Arora S, Maltsev DS, Sahoo NK, Parameshwarappa DC, Iovino C, Arora T, et al. Visual acuity correlates with multimodal imaging-based categories of central serous chorioretinopathy. Eye. 2022;36:517–23.
doi: 10.1038/s41433-021-01788-4
pubmed: 34645969